The aim of this study was to establish the effect of naturally occurring antioxidant -carnosine -on the doxorubicin induced cardiotoxicity in a rabbit model. For this purpose we evaluated the influence of doxorubicin administration alone and in a combined therapy with carnosine on the haemodynamic parameters and on the degree of cardiac muscle cells alterations in rabbits. The rabbits were divided into four groups. One group of rabbits was injccted with doxorubicin in a dose of 2 mg kg -1 weekly for 7 weeks to induce congestive heart failure. Another group of rabbits received the same doses of doxorubicin simultaneously with carnosine in a dose of 100 mg kg 1 p.o. daily for 9 weeks. Administration of carnosine was started 1 week prior to the first dose of doxorubicin and was ended one week after the administration of the last dose of doxorubicin. The control groups of animals received 0.9% NaCl and carnosine alone. The following haemodynamic parameters were estimated: heart rate, mean arterial pressure, cardiac index, stroke index and total peripheral resistance. Registration of the haemodynamic parameters in rabbits was performed by Doppler method. Carnosine normalised the values of mean arterial pressure in rabbits receiving doxorubicin, and increased the values of cardiac index and stroke index. The influence of carnosine on total peripheral resistance was not statistically significant, but there was a decreasing tendency. The degree of cardiac muscle cell alterations was examined by light microscopy using Mean Total Score technique. The histopathological studies revealed smaller damage of cardiac muscle in rabbits which received doxorubicin and carnosine, in comparison to animals receiving doxorubicin alone. Carnosine seems to be car dioprotective during doxorubicin administration.
Introduction
Doxorubicin is an anthracycline antibiotic with a potent anticancer activity used widely in medical oncology. Doxorubicin is used against human neoplasms including a variety of solid tumours (e.g. head and neck tumors), breast cancer, bladder and testicular cancer, SCLC (1) . Doxorubicin is effective in acute lymphoblastic and non-lymphoblastic leukaemias and malignant lymphomas (2) . The most dangerous, unique and often irreversible toxic effect of doxorubicin that significantly limits its therapeutic use is dose-related cardiomyopathy, which occurs in c.a. 20% of patients with a cumulative doxorubicin dose of 450 to 500 mg m 2 . Doxorubicin may provoke a few types of cardiomyopathies. An acute form is due to rapid intravenous administration of doxorubicin and is manifested by vasodilatation and hypotension. It is characterized by arrhythmias, disturbances in impulse conduction and congestive heart failure with pericardial effusion. Subacute cardiotoxicity develops during chemotherapy and is characterized by myocarditis and pericarditis. Chronic cardiotoxicity develops towards the end of therapy and after its termination and is manifested by dilated cardiomyopathy with loss of cardiac muscle cells, cytoplasmic vacuolization, subsequent replacement by fibrous tissue and congestive heart failure (3, 4) . The mechanism of doxorubicin cardiotoxicity has not been explained. The generation of reactive oxygen species through the interaction of the drug with iron and doxorubicin reduction to C-13 alcohol metabolite via an intermediate semiquinone moiety play a very important role in the pathogenesis of cardiac toxicity, mainly of its chronic form (5, 6). There have been attempts to reduce the cardiotoxicity of anthracycline antibiotics (7) . One of the applied methods to minimise the doxorubicin cardiotoxicity is using cardioprotective substances which can selectively protect healthy cells against the cytotoxicity of doxorubicin without reducing the antitumour activity of the drug ( 8) . Carnosme, a dipeptide of L-histidine and balanine. is naturally occurring antioxidant found mainly in muscles, brain and other innervated animal and human tissues (9, 10). Carnosine acts as a buffer of muscle tissue and a binder of heavy metal ions. The aim of this study was to investigate if carnosine can reduce the cardiotoxicity effect during the doxorubicin administration in rabbits. For this purpose we evaluated the influence of doxorubicin administration alone and in a combined therapy with carnosinc on the haemodynamic parameters and on the degree of cardiac muscle cells alterations in rabbits.
Materials and Methods

Materials
Doxorubicin
(Ebewe, Austria), carnosine (Cambridge Major Laboratories INC), urethane (ethyl carbamate, Sigma, USA), a-chloralose (Roth, Germany).
Animal experiments
The study was performed in 31 outbred chinchilla rabbits of both sexes with body weight ranging between 2.5-3.5 kg, aged 15-20 weeks. The animals were housed in standard cages, one animal per cage, in a 12 h light-darkness cycle. The rabbits were fed with granulated mix "LSK" with free access to water. The weight of animals was checked weekly. All the experiments were carried out between 9 and 12 a.m.
Experimental procedures were carried out in accordance to international guidelines for care and use of laboratory animals. All efforts were made to minimise animal suffering and to reduce the number of animals used in the experiment. All the procedures in this experiment were approved by The Ethics Committee of the Medical University of £ódY. The animals were divided into four groups with 6-11 rabbits randomly allocated to every group, receiving the following doses of drugs (Table 1) Group 1: 0.9% NaCl i.v. weekly for 7 weeks (control group), group 2: Doxorubicin 2 mg kg 1 weekly i.v. for 7 weeks, group 3: Doxorubicin 2 mg kg' 1 weekly i.v. for 7 weeks and simultaneously carnosinc 100 mg kg' 1 p.o. daily for 9 weeks, group 4: Carnosine 100 mg kg 1 p.o. daily for 9 weeks. Doxorubicin and 0.9% NaCl were administered into the marginal ear vein by bolus injection. Carnosine was administered by oral gavage in aqueous solution. Administration of carnosine was started 1 week prior to the first dose of doxorubicin and was ended one week after the administration of the last dose of doxorubicin.
Surgery was performed two weeks after the administration of the last dose of doxorubicin or after the same period of saline injections in the control group. The rabbits were placed on the operation table in a dorsal position. The animals were anaesthetized with ?-chloralose (40mg kg 1 ) and urethane (400mg kg r ) administered into the marginal ear vein. Anaesthesia was maintained by additional bolus doses of urethane as needed during surgery. The level of anaesthesia was demonstrated by lack of muscle movement and haemodynamic responses. Tracheostomy was needed because the thoracic cavity was opened. Control ventilation was made using C.F. Palmer London LTD pomp. Ventilation frequency was set at 30 bpm and tidal volume at 50-60 ml. ECG was recorded using Multicard E300. Extremity leads and precordial leads were regis-Graczyk J. et al·. Effects of Carnosine on the Toxicit> c: Γ· ----. , : nd Mice tered before opening of the thoracic cavity in order to estimate ECG after completed 7-week cycle of doxorubicin administrations. After the opening of the thoracic cavity extremity leads were registered to estimate ECG during surgery.
Haemodynamic studies The registration of haemodynamic parameters in rabbits was performed by using Hugo Sachs Elektronik Haemodyn (Harvard Apparatus GmbH, March, Germany). A heparinized polyethylene catheter was placed into the dissected carotid artery and connected to an Isotec pressure transducer (HSE Harvard Apparatus) for arterial blood pressure measurement (SYS, DIA, MAP). Median sternotomy and pericardiotomy was performed to place the flow probe around the ascending aorta for aortic blood flow (AF min AF mean AF max ) measurement taken as an index of cardiac output. It was connected to an ultrasonic flowmeter Transit Time Flowmeter TTFM Type 700 (HSE Harvard Apparatus and Transonic System Inc. USA). Heart rate (HR) was registered from the catheter placed in the carotid artery. All analogue signals were amplified and recorded on a computer via an A/D converter (HSE-Haemodyn software for Microsoft Windows 95/98/NT) and they were evaluated according to the algorithms. The rabbits received a continuous infusion of normal saline into the marginal car vein to compensate the fluid loss during surgery. The derivative haemodynamic parameters were calculated: cardiac index (CI), stroke index (SI), total peripheral resistance (TPR), After surgery the animals were killed by over dosage of penthobarbital sodium (160 mg/kg) administered into the marginal ear vein.
Histopathoiogical studies Hearts were taken immediately post-mortem, weighed and fixed in a buffered 10% solution of formalin for histopathoiogical estimation. Two segments from the right and left ventricle, interventricular septum and left papillary muscle were taken after macroscopic estimation. Using Mean Total Score (MI'S) technique, the degree of cardiac muscle cell alterations was examined by light microscopy (11, 12, 13 
Results
Results of haemodynamic studies
The results of haemodynamic studies were based on the composition of the values of five parameters: heart rate (HR), mean arterial pressure (MAP), cardiac index (CD, stroke index (SI) and total peripheral resistance (TPR) and have been presented in (Table 2) .
Heart rate (HR) HR did not differ in a statistically significant way between the examined groups of rabbits, however there was a trend towards a decrease in HR in rabbits receiving doxorubicin.
Mean arterial pressure (MAP)
The value of MAP was 97.8 ± 12.0 mmHg in the control group of rabbits and it did not differ statistically significant from the value of MAP registered in the group of rabbits receiving carnosine. Doxorubicin administration to rabbits resulted in a statistically significant decrease in MAP to 61.7 ± 27.7 mmHg. Carnosine administration to the group of rabbits receiving doxorubicin caused statistically significant increase in MAP to 97.0 ± 23.0 mmHg. This value of MAP did not differ from the value of MAP registered in the control group and in the group receiving carnosine.
Cardiac index (CI)
CI was 79.0 ± 4.1 rnl/min/kg in the control group of rabbits and did not differ from the value of CI calculated for the group of rabbits receiving carnosine. Doxorubicin administration to rabbits caused statistically significant decrease in CI to 37.5 ± 5.4 ml/min/kg. Carnosine administration to the group of rabbits receiving doxorubicin resulted in a statistically significant increase in CI to 59.4 ± 5.4 ml/min/kg, which did not differ from CI in the control group and in the group receiving carnosine.
Stroke index (SI)
SI was 0.29 ± 0.03 ml/kg/cykl in the control group of rabbits and did not differ from the in the group of rabbits receiving carnosine. Doxorubicin administration to rabbits caused a decrease in SI to 0.15 ± 0.02 ml/kg/cykl. Carnosine administration to the group of rabbits receiving doxorubicin caused an increase in SI to 0.22 ± 0.03 ml/kg/cykl. This SI differed from the control group and also from the group receiving doxorubicin, but it was not different from SI in the group receiving carnosine.
Total peripheral resistance (TPR) TPR did not differ in the examined groups of rabbits, although there was a trend towards an increase in TPR in the group of rabbits receiving doxorubicin. TPR was not lower after simultaneous administration of doxorubicin and carnosine.
Results of histopathological studies The intensity and extensiveness of histological changes in sections from rabbits' hearts were evaluated seini-quantitatively using the modified MTS scale (Mean Total Score). MTS scale is used to evaluate the intensity of changes in cardiomyocytes (N) in a scale from 1 to 2 and extensiveness of changes (R) in a scale from 0 to 5: MTS = Σ( Ν χ R) / number of sections evaluated in each rabbit
In rabbits from the control group (n=6) and the group receiving carnosine (n=6) histopathological evaluation of sections from the left and right ventiick. intraventricular septum and papillary muscle of the left ventricle did not reveal any pathological changes.
In all rabbits receiving doxorubicin (n=10) microscopic examination of sections from hearts revealed macrovacuolic and microvacuolic changes in the cyloplasm of cardiomyocytes and interstitial oedema. In 7 animals additionally necrosis of cardiomyocytes v. as found. The extensiveness of changes varied from small lesions, of not more than 10 cardiomyocytcs in a preparation, to large lesions forming foci of damaged heart muscle cells. In no case there was proliferation of interstitial fibrous connective tissue (Fig. 1) .
In rabbits receiving simultaneously doxorubicin and carnosine (n=9) there were also macrovacuolic and microvacuolic changes in cardiomyocytcs and interstitial oedema. However, in comparison with rabbits receiving doxorubicin alone the extensiveness of changes was small and concerned single cells. In rabbits from this group in heart sections there was no necrosis in cardiomyocytes, either. In 2 animals there were extensive devascularisations under the epicardium and endocardium of both right and left vcntriclcs. The above mentioned changes were not typical for doxorubicin-induced lesions, and thus they were not included in microscopic studies and in statistical analysis of results. In no case there was proliferation of interstitial fibrous connective tissue (Fig. 2) .
"' ¿-··· Figure 1 . Microscopic examination of sections from rabbit heart after receiving doxorubicin Table 3 . presents mean values of MTS for rabbits receiving doxorubicin and doxorubicin with carnosine. 
Discussion
Numerous mechanisms of cardiotoxic activity of anthracycline antibiotics have been proposed. The most important and probable seems to be the mechanism based on the generation by doxorubicin of oxidative stress in the heart muscle and stimulation of apoptosis in cardiomyocytes (14) . Because of poor antioxidant protection in cardiac myocytes (low concentration of superoxide dismutase, catalase and glutathione peroxidase) reactive oxygen species cause lipid peroxidation and mitochondrial destruction (15) . There are some ways of reducing the cardiotoxicity of doxorubicin: monitoring chemotherapy, modifying the schedule of administration, patients selection considering Figure 2 . Microscopic examination of sections from rabbit heart after receiving doxorubicin and carnosine simultaneously risk factors, liposomal encapsulation of doxorubicin, using less toxic doxorubicin analogues (7, 16 ). An important method of decreasing the cardioloxicity of doxorubicin is administration of this drug with cvtoprotective agents, which selectively protect normal cells from toxicity of the drug. Dexrazoxane (Cardioxane) was synthesized as a specific water-soluble cardioprotective agent which protects against irondependent oxygen free radical-mediated anthracycline-induced cardiotoxicity (17) . Unfortunately, dexrazoxane does not reduce gastrointestinal toxicity and myelotoxicity of doxorubicin (18) . Besides, the influence of dexrazoxane on antitumour activity of doxorubicin is not quite clear ( 19, 20, 21) . New cytoprotective compounds are being investigated. Researchers concentrate on numerous antioxidative compounds, such as melatonin, coenzyme Q, amifostin, flavonoid compounds, essential fatty acids, L-carnitine, selenium (22, 23, 24) . In our research we concentrated on carnosine, a dipeptide commonly occurring in human body, which also shows antioxidative properties. Carnosine is a water-soluble free radicals scavenger and prevents lipid peroxidation of the cell membranes (25, 26, 27) . Carnosine may act not only as a scavenger of reactive oxygen species, but also may prevent their formation. In vitro, carnosine prevents the generation of strongly oxidating hydroxyl radical by chelating of transitional metals ions (Cu, Zn, Fe) (28) . It also prevents the generation of peroxynitril radical, and thus it may exert a protective effect on the endothelium (29) . Moreover, carnosine, antioxidant well soluble in water, prevents modification and loss of activity of proteins responsible for sequestration of metals in blood plasma (for example ceruloplasmine) due to effect of free radicals or toxic products of lipids peroxidation (30) . In vitro, carnosine inactivates dangerous highly reactive lipid peroxidation products (malondialdehyde, 4-hydroxynonenal, acroleine) (31) . Malondialdehyde and similar compounds attack biomolecules in the process of nonenzymatic glycosylation -glycation -causing the accumulation of carbonyi groups on proteins and formation of advanced glycosylation end products (AGEs). Carnosine, an effective antiglycation factor, prevents carbonylation of biomolccules by entering a reaction with reactive aldehydes and eliminates AGEs formed in the process of carnosylation of modified proteins (32) . Carnosine protects against cross-linking of proteins (33) . Accumulation of AGEs is a biochemical manifestation of the process of ageing of cells. Antioxidant and antiglycating propertics of carnosine may be responsible for its antiaging properties (34, 35). Carnosine may also inhibit mitochondrial apoptosis pathways (36). Besides, in vitro studies revealed that, carnosine can increase contractility of isolated cardiac muscle of rat by directly acting on the ryanodine receptor and releasing calcium. Carnosine can play a role of modulator of calcium-regulated proteins in cardiac muscle cells (37). Carnosine was administered to animals and humans in several experiments. The efficacy of N-acetylcarnosine in the fonti of eye drops in the treatment of cataract in people was demonstrated in a randomised placebo controlled study. Ν -aeety (carnosine improved the visual acuity and glare sensitivity and reduced lens opacity (38). Zinc L-carnosine (polaprezinc) acts as a gastric mucosal protector against various irritant factors. Orally administered polaprezinc Helicobacter pylori induced gastric mucosal inflammation in Mongolian Gerbils (39). Polaprezinc in combination with lansoprazole, amoxycillin and clarithromycin increased the effectiveness of Helicobacter pylori eradication in people (40). Polaprezinc improved the impaired healing of chronic gastric ulcers in arthritis rats (41). The beneficial effects of polaprezinc on gastric mucosal injury may be due to its antioxidative properties. Polaprezinc was effective in acetic acid-induced stomatitis in hamsters. This suggests that polaprezinc might be applicated in severe stomatitis induced by anticancer drugs (42). Carnosine was investigated for anti-ischaemic activity. Carnosine reduced mortality of animals during experimental cerebral ischaemia and decreased the consequences of cardiac ischaemia, it protected cardiomyocytes and enhanced the contractility of the heart muscle (43). Carnosine can be a neuropotective agent. The effect of carnosine supplementation was investigated in children with autistic spectrum disorders in a double-blind, placebo-controlled study. Carnosine was administered for 8 weeks enhanced neurologic function (44).
We have tested possible cardioprotection by carnosine during doxorubicin administration in rabbits. Rabbits received 2 mg kg-1 of doxorubicin weekly i.v. for seven weeks to induce congestive heart failure (45) and carnosine p.o. in a dose of 100 mg kg 1 . Carnosine administered per os is absorbed mainly in the small intestine. During absorption, partial hydrolysis of dipeptide to ß-alanine and L-histidine takes place (46, 47 48). This fact was taken into consideration; carnosine was administered in the dose of 100 mg kg-1, i.e. 5-times higher than the dose administered intraperitoneally to rats and rabbits. Carnosine reduced the disadvantageous haemodynamic changes in rabbits during doxorubicin administration. Carnosine normalised mean arterial blood pressure in rabbits receiving doxorubicin. and increased the values of cardiac index and stroke index. The effect of carnosine on the value of total peripheral resistance was not statistically significant, but resistance tended to decrease. The results of haemodynamic studies may indicate a positive interaction between carnosine and doxorubicin in decreasing the cardiotoxicity of the antitumour drug. The conducted histopathological studies revealed smaller damage of the heart muscle in rabbits which received doxorubicin in combination with carnosine. as compaiod to those receiving doxorubicin as monotherapy. It ¡nay indicate that carnosine decreases the cardiotoxicity <.Ί doxorubicin in rabbits.
In conclusion, carnosine seems to show Cardioprotect ¡ve effect during doxorubicin administrati;>p. Further research shall be carried out to explain the cardioprotective action of this dipeptide.
